Hyperfractionated radiotherapy for lung cancer.

被引：10
作者：
Gressen E.L. [1 ]
Curran W.J. [1 ]
机构：
[1] Department of Radiation Oncology, Frankford Hospital Torresdale Division, Knights and Red Lion Roads, Philadelphia, 19114, PA
来源：
Current Oncology Reports | 2000年 / 2卷 / 1期
关键词：
CDDP; Median Survival Time; Radiat Oncol Biol Phys; Radiation Therapy Oncology Group; Amifostine;
D O I：
10.1007/s11912-000-0013-0
中图分类号：
学科分类号：
摘要：
In several recent clinical trials, hyperfractionated or accelerated hyperfractionated thoracic radiation therapy has improved survival over conventional radiotherapy among patients with either stage III non-small-cell lung cancer or limited-stage small-cell lung cancer. Combinations of novel chemotherapy agents such as taxanes and gemcitabine with hyperfractionated or accelerated hyperfractionated radiotherapy may further improve survival, although toxicity must be closely followed. Attempts to minimize the amount of normal tissue radiated through either three-dimensional treatment planning or use of a radioprotector (such as amifostine) may allow therapeutic escalation with chemoradiation and further success at treating the number one cause of cancer-related mortality in the United States.
引用
收藏
页码：71 / 75
页数：4
相关论文
共 41 条
  • [1] Bonner JA(1998)The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung cancer, results of a north central cancer treatment group phase III study Cancer 82 1037-1048
  • [2] McGinnis WL(1995)Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer J Natl Cancer Inst 87 198-205
  • [3] Stella PJ(1996)Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1210-1215
  • [4] Sause WT(1997)Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial Lancet 350 161-165
  • [5] Scott C(1997)Induction cisplatin /vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588 Int J Radiat Oncol Biol Phys 39 537-544
  • [6] Taylor S(1995)Randomized trial of hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III non-small cell lung cancer J Clin Oncol 13 452-458
  • [7] Dillman RO(1998)Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): long-term results of a phase II study Int J Radiat Oncol Biol Phys 42 1091-1096
  • [8] Herndon J(1998)Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung Int J Radiat Oncol Biol Phys 42 469-478
  • [9] Seagren SL(1999)A quality-adjusted re-analysis of a phase III trial comparing once-daily thoracic radiation therapy versus twice-daily thoracic radiation therapy in patients with limited stage small cell lung cancer [abstract.] Proc ASCO 18 1799a-1799a
  • [10] Saunders M(1998)Alternating radiotherapy and chemotherapy for inoperable stage III nonsmall-cell lung cancer: long-term results of two phase II Gotha trials Int J Radiat Oncol Biol Phys 42 487-494
12345